250 results
8-K
EX-99.1
ACGN
Aceragen Inc
17 Nov 20
Idera Pharmaceuticals Announces Dan Soland to Join as Chief Operating Officer
4:20pm
three years. In his role as COO, he will be responsible for commercial strategy and manufacturing as Idera plans for success in anticipation of data … and leadership to our Idera team,” stated Mr. Milano. “Dan’s leadership of our marketing, sales, manufacturing, and distribution strategy and operations
8-K
EX-99.1
ACGN
Aceragen Inc
9 Jan 14
Idera Expands Leadership Team and Strengthens Clinical Development Expertise in Oncology and Orphan Diseases
12:00am
Brenner, MD, and New Board Member Mark Goldberg, MD, to help guide clinical development strategy and execution
CAMBRIDGE, Mass.—(BUSINESS WIRE)—Jan … clinical development strategy, regulatory affairs, medical affairs, and product commercialization. Dr. Brenner joins Idera from Radius Health, where
8-K
EX-99.1
ACGN
Aceragen Inc
29 Oct 20
Idera Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update
4:40pm
Corporate Update
ILLUMINATE-301 Continues on Track and Beyond Melanoma Strategy Advances
EXTON, PA, October 29, 2020 — Idera Pharmaceuticals, Inc … and neck cancers as well as the continuation of ILLUMINATE-206 reinforce our ‘beyond melanoma’ strategy. We also have the financing to help our outstanding
8-K
EX-99.1
ACGN
Aceragen Inc
4 Sep 19
Idera Pharmaceuticals Announces Immuno-Oncology Clinical Research Collaboration with AbbVie
7:05am
clinical collaboration, which continues to advance our strategy of exploring the possibilities to further improve patient outcomes harnessing the immune … , included or incorporated in this press release, including statements regarding the Company’s strategy, future operations, collaborations
425
ACGN
Aceragen Inc
22 Jan 18
Business combination disclosure
12:00am
no different for either company as a stand-alone.
3) Strategic Fit / NewCo Strategy
a. How will this merger benefit patients? We believe … or otherwise change the strategy around programs that do not fit into that category? We are excited about the combined opportunities
425
mzo8tw7k
22 Jan 18
Business combination disclosure
12:00am
8-K
EX-99.1
fdanthoarc844un8p
28 Sep 20
Idera Pharmaceuticals Announces New U.S. Patent Coverage for Tilsotolimod Through September 2037
8:50am
8-K
EX-99.2
20c3my
5 Feb 14
Other Events
12:00am
8-K
EX-99.2
nwsqfypb5jmu
24 Sep 13
Other Events
12:00am
8-K
EX-99.1
iewywd
4 Aug 20
Idera Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update
4:31pm
8-K
EX-99.1
h7ybho avh
1 Mar 21
Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
4:37pm
8-K
EX-99.1
iipka72epobe pj
31 Oct 19
October 2019 Corporate Update
5:14pm
425
lhas kowg9cwpq8
22 Jan 18
Business combination disclosure
12:00am
425
w8gp dsm5
22 Jan 18
Business combination disclosure
12:00am
8-K
EX-99.3
b5wpsexjjt 503i
5 Feb 14
Other Events
12:00am
8-K
EX-99.1
8i8j4a
11 Jan 21
Idera Pharmaceuticals to Present at Upcoming Conferences
6:04am
8-K
7ypt2fnqvudk19wqkp
9 Jan 19
Departure of Directors or Certain Officers
4:06pm
425
yy8u oghegk
7 Jun 18
Business combination disclosure
8:17am